<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the study was to evaluate the activity of <z:chebi fb="0" ids="50131">decitabine</z:chebi>, a hypomethylating agent, in the treatment of patients with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in transformation </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-seven patients with <z:mp ids='MP_0005481'>CML</z:mp> in blastic (20 patients) or accelerated phases (17 patients) were treated </plain></SENT>
<SENT sid="2" pm="."><plain>Their median age was 52 years; 36 had <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome-positive</z:e> disease </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> was given at 100 mg/m2 over 6 h every 12 h x 10 doses (1000 mg/m2) to 13 patients, and at 75 mg/m2 over 6 h every 12 h x 10 doses (750 mg/m2) to 24 patients </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e>, two patients (10%) achieved a complete hematologic response (one with Ph suppression), and three (15%) had a hematologic improvement (marrow CR, platelets &lt;100 x 10[3]/microl), for an overall response rate of 25% </plain></SENT>
<SENT sid="5" pm="."><plain>In accelerated phase, six patients (35%) returned to a second <z:hpo ids='HP_0011010'>chronic</z:hpo> phase (two with Ph suppression), one (6%) had a hematologic improvement, and two (12%) had a partial hematologic response, for an overall response rate of 53% </plain></SENT>
<SENT sid="6" pm="."><plain>Prolonged <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> was the most significant side-effect </plain></SENT>
<SENT sid="7" pm="."><plain>The median time to recovery of granulocytes above 500/microl was 48 days, and to recovery of platelets above 30 x 10(3)/microl, 31 days </plain></SENT>
<SENT sid="8" pm="."><plain>Febrile episodes occurred in 25 patients (68%) including documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in 17 patients (46%) </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> has promising activity in <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>The most significant side-effect is prolonged <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> may show activity in other myeloid disorders such as <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, as well as in other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, alone or with other drug combinations </plain></SENT>
<SENT sid="12" pm="."><plain>Its value in the context of stem cell support should also be investigated </plain></SENT>
</text></document>